Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Liquidia's Business Segments
Liquidia's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 133
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 133 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product97.8%
- Service2.2%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 130 | 97.8% |
| Service | $ 3 | 2.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Liquidia
Liquidia Corporation is a biopharmaceutical company that specializes in the development and commercialization of products using its proprietary PRINT® (Particle Replication in Non-wetting Templates) technology. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.
The PRINT technology platform is a particle engineering technology that enables the precise design and manufacture of uniform nanoparticles with customizable attributes. This unique technology allows for the creation of nanoparticles with well-defined size, shape, and surface chemistry, which can be used for a variety of applications in drug delivery, vaccines, and diagnostics.
Liquidia primarily focuses on the development of therapeutics for the treatment of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension (PAH). They aim to improve on currently available treatments by enhancing drug delivery to the lungs and optimizing therapeutic efficacy.
One of the key advantages of Liquidia's PRINT technology is the ability to create inhaled therapies that can be delivered directly to the lungs. By precisely controlling the size and shape of nanoparticles, Liquidia can increase drug deposition in the lungs and improve drug absorption, leading to better treatment outcomes.
In addition to respiratory therapies, Liquidia is also exploring the use of its technology in other therapeutic areas, including oncology and rare diseases. They have partnerships with various pharmaceutical companies to develop and commercialize products using their PRINT technology.
In terms of pipeline, Liquidia has several lead product candidates in various stages of development. Their most advanced candidate is LIQ861, an inhaled formulation of treprostinil for the treatment of PAH. LIQ861 has completed Phase 3 clinical trials and is currently awaiting regulatory approval.
Liquidia also has a collaboration with GlaxoSmithKline (GSK) to develop inhaled therapies for the treatment of asthma and COPD. Under this collaboration, Liquidia has received funding and is responsible for developing and manufacturing the nanoparticles, while GSK is responsible for formulating the nanoparticles into inhalable medicines.
Overall, Liquidia Corporation is a biopharmaceutical company at the forefront of nanoparticle engineering technology. With their innovative PRINT platform, they aim to revolutionize drug delivery and improve patient outcomes in respiratory and other diseases.
The PRINT technology platform is a particle engineering technology that enables the precise design and manufacture of uniform nanoparticles with customizable attributes. This unique technology allows for the creation of nanoparticles with well-defined size, shape, and surface chemistry, which can be used for a variety of applications in drug delivery, vaccines, and diagnostics.
Liquidia primarily focuses on the development of therapeutics for the treatment of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension (PAH). They aim to improve on currently available treatments by enhancing drug delivery to the lungs and optimizing therapeutic efficacy.
One of the key advantages of Liquidia's PRINT technology is the ability to create inhaled therapies that can be delivered directly to the lungs. By precisely controlling the size and shape of nanoparticles, Liquidia can increase drug deposition in the lungs and improve drug absorption, leading to better treatment outcomes.
In addition to respiratory therapies, Liquidia is also exploring the use of its technology in other therapeutic areas, including oncology and rare diseases. They have partnerships with various pharmaceutical companies to develop and commercialize products using their PRINT technology.
In terms of pipeline, Liquidia has several lead product candidates in various stages of development. Their most advanced candidate is LIQ861, an inhaled formulation of treprostinil for the treatment of PAH. LIQ861 has completed Phase 3 clinical trials and is currently awaiting regulatory approval.
Liquidia also has a collaboration with GlaxoSmithKline (GSK) to develop inhaled therapies for the treatment of asthma and COPD. Under this collaboration, Liquidia has received funding and is responsible for developing and manufacturing the nanoparticles, while GSK is responsible for formulating the nanoparticles into inhalable medicines.
Overall, Liquidia Corporation is a biopharmaceutical company at the forefront of nanoparticle engineering technology. With their innovative PRINT platform, they aim to revolutionize drug delivery and improve patient outcomes in respiratory and other diseases.
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, particularly in the areas of pulmonary and cardiovascular diseases. The company utilizes its proprietary PRINT® technology, which allows for the precise engineering of drug particles, to create products that deliver superior efficacy and safety profiles.
Segments
1. Pharmaceutical Development: Liquidia is primarily focused on developing treatments for various conditions, particularly in the area of pulmonary hypertension and related disorders. This segment targets specific patient populations with unmet medical needs and seeks to offer solutions that improve quality of life.
2. Commercialization: This segment encompasses the marketing and distribution of Liquidia’s approved products. The goal here is to ensure that healthcare providers and patients have access to their therapies, coupled with educational resources that promote proper usage.
3. Research and Development (R&D): Liquidia is heavily invested in R&D to discover and develop new formulations and therapies. This segment emphasizes innovation in drug delivery systems, leveraging the PRINT technology to explore new applications across different therapeutic areas beyond pulmonary diseases.
Products
1. LIQ861 (Treprostinil): This product is a novel, inhaled dry powder formulation of treprostinil, which is used for the treatment of pulmonary arterial hypertension (PAH). Liquidias formulation aims to enhance deliverability and efficacy compared to existing treatments by allowing for targeted delivery to the lungs with minimized side effects. The product has received approval from regulatory authorities and is positioned as a key component of Liquidias product pipeline.
2. Pipeline Products: Liquidia maintains a robust pipeline of drugs in various stages of development. This includes additional formulations and potential therapies targeting pulmonary diseases and other therapeutic areas. These pipeline products represent the company’s commitment to addressing significant medical challenges and pursuing breakthroughs in treatment options.
Services
1. Clinical Support Services: Liquidia offers clinical support to patients and healthcare providers to facilitate the optimal use of its therapies. This includes providing detailed prescribing information, educational resources about the conditions treated, and support for navigating insurance and reimbursement pathways.
2. Collaborative Research: Through partnerships and collaborations with other pharmaceutical companies and academic institutions, Liquidia engages in joint research initiatives to explore further applications of its technologies. This helps in broadening the reach of PRINT technology and its potential applications across various therapeutic areas.
3. Regulatory Support: Liquidia provides regulatory guidance throughout the development process of its products, ensuring compliance with the necessary standards and regulations set forth by health authorities. This support is crucial in navigating the complex landscape of drug approval and market entry.
Conclusion
Liquidia Corporation emphasizes innovation in drug development through its PRINT technology, aiming to improve the treatment landscape for patients with pulmonary and cardiovascular diseases. By focusing on both established and emerging products, alongside supportive services, the company seeks to enhance the overall health outcomes of its target populations. Its segments—ranging from pharmaceutical development to commercialization and research—underscore its commitment to addressing unmet medical needs and advancing healthcare solutions.
Segments
1. Pharmaceutical Development: Liquidia is primarily focused on developing treatments for various conditions, particularly in the area of pulmonary hypertension and related disorders. This segment targets specific patient populations with unmet medical needs and seeks to offer solutions that improve quality of life.
2. Commercialization: This segment encompasses the marketing and distribution of Liquidia’s approved products. The goal here is to ensure that healthcare providers and patients have access to their therapies, coupled with educational resources that promote proper usage.
3. Research and Development (R&D): Liquidia is heavily invested in R&D to discover and develop new formulations and therapies. This segment emphasizes innovation in drug delivery systems, leveraging the PRINT technology to explore new applications across different therapeutic areas beyond pulmonary diseases.
Products
1. LIQ861 (Treprostinil): This product is a novel, inhaled dry powder formulation of treprostinil, which is used for the treatment of pulmonary arterial hypertension (PAH). Liquidias formulation aims to enhance deliverability and efficacy compared to existing treatments by allowing for targeted delivery to the lungs with minimized side effects. The product has received approval from regulatory authorities and is positioned as a key component of Liquidias product pipeline.
2. Pipeline Products: Liquidia maintains a robust pipeline of drugs in various stages of development. This includes additional formulations and potential therapies targeting pulmonary diseases and other therapeutic areas. These pipeline products represent the company’s commitment to addressing significant medical challenges and pursuing breakthroughs in treatment options.
Services
1. Clinical Support Services: Liquidia offers clinical support to patients and healthcare providers to facilitate the optimal use of its therapies. This includes providing detailed prescribing information, educational resources about the conditions treated, and support for navigating insurance and reimbursement pathways.
2. Collaborative Research: Through partnerships and collaborations with other pharmaceutical companies and academic institutions, Liquidia engages in joint research initiatives to explore further applications of its technologies. This helps in broadening the reach of PRINT technology and its potential applications across various therapeutic areas.
3. Regulatory Support: Liquidia provides regulatory guidance throughout the development process of its products, ensuring compliance with the necessary standards and regulations set forth by health authorities. This support is crucial in navigating the complex landscape of drug approval and market entry.
Conclusion
Liquidia Corporation emphasizes innovation in drug development through its PRINT technology, aiming to improve the treatment landscape for patients with pulmonary and cardiovascular diseases. By focusing on both established and emerging products, alongside supportive services, the company seeks to enhance the overall health outcomes of its target populations. Its segments—ranging from pharmaceutical development to commercialization and research—underscore its commitment to addressing unmet medical needs and advancing healthcare solutions.